Aaron Royston, M.D., M.B.A. is a Managing Partner at venBio with a background in life science investing, healthcare strategy, and as an entrepreneur. Since joining venBio, he has been involved in launching and investing in a number of venBio companies including Apellis Pharmaceuticals (IPO 2017), Menlo Therapeutics (IPO 2018), Akero Therapeutics (IPO 2019), Harmony Biosciences (IPO 2020), RayzeBio, Artiva Biotherapeutics, Neurogastrx, Impel NeuroPharma, and Swift Health Systems. Prior to joining venBio, Dr. Royston was a member of the investment team at Vivo Capital, a life science venture capital firm. Previously, he worked at Bain & Company, where he advised biotechnology companies on a range of strategic and operational issues. Earlier in his career, he coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences.
Dr. Royston received his B.S. in biological sciences from Duke University, and his M.D. and M.B.A. degrees from the University of Pennsylvania. While a student, he founded and launched a technology company that was acquired after receiving multiple awards and funding from the New York City Economic Development Corporation. In 2010, he was recognized by the United States White House as a Champion of Change for his work in Technology and Innovation. Dr. Royston is active in the community and serves on the board of SFBWS, an environmental non-profit authorized by Congress to support the education, interpretation, and research of the U.S. Fish and Wildlife Service.